Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Providence Therapeutics Holdings Inc.
5 records totalling $77,088,801.00 CAD, from official Government of Canada open data.
Embed this chart
By department
| Innovation, Science and Economic Development Canada | $49,900,000 | 1 record |
| National Research Council Canada | $27,188,801 | 4 records |
Records
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in m...
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a...
Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical effi...
This proposal aims to develop a made-in-Canada solution to the threat posed by Highly Pathogenic Avian Influenza (HPAI) to Canadian livestock. Providence Therapeutics will initiate work to design and...